Systemic treatment of malignant melanoma: Grade is as important as stage

Clinical and Experimental Dermatology

Volumn 22, Issue 2, 1997, Pages 67-71

  Retsas, Spyros ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; DACARBAZINE; FOTEMUSTINE; NAVELBINE; PACLITAXEL; PLATINUM; VINBLASTINE; VINCRISTINE; VINDESINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DRUG RESPONSE; HUMAN; MELANOMA; PRIORITY JOURNAL; PROGNOSIS;

AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 0030824208     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.1997.tb02622.x     Document Type: Article

References (17)

1. Retsas S. On the antiquity of cancer; from Hippocrates to Galen. In: Retsas S, ed. Palaeo-oncology: The Antiquity of Cancer. London: Farrand Press, 1986; 41-58.
2. Retsas S, Gershuny A. Central nervous system involvement in malignant melanoma. Cancer 1988; 61: 1926-1934.
3. Damato BE. Prognostic factors for primary uveal melanoma. Melanoma Research 1995; 5: 441.
4. Retsas S, Henry K, Mackenzie DH. Missed malignant melanoma. Brit Med J 1986; 292: 1270-1271. ibid. Brit Med J; 293: 50-51.
5. Retsas S, Henry K, Mackenzie DH. Missed malignant melanoma. Brit Med J 1986; 292: 1270-1271. ibid. Brit Med J; 293: 50-51.
6. Retsas S. Early or low-grade melanoma? The Lancet 1987; 2: 276-277.
7. Burton R, Armstrong B. Recent incidence trends imply a non-metastasizing form of invasive melanoma. Melanoma Research 1994; 4: 107-13.
8. Retsas S. Strategies for improving survival in malignant melanoma: focus on vindesine. J Drug Dev Clin Pract 1995; 7: 159-71.
9. Retsas S, Bayliss M, Sheikh N et al. Chemotherapy of malignant melanoma; the European experience. Rev Med Int 1990; XI (Suppl 2): 51-8.
10. Eton O, Legha S, Papadopoulos N et al. Long term survival in patients with metastatic melanoma at MD Anderson Cancer Centre: 1979-1989. Proceedings of the Twenty-eighth Annual Meeting of the American Society of Clinical Oncology. Philadelphia, PA: W. B. Saunders Co., 1992: 1183.
11. Retsas S, Mohith A, Mackenzie H. Taxol and vinorelbine: a new active combination for disseminated malignant melanoma. Anti-Cancer Drugs 1996; 7: 161-5.
12. Legha S, Ring S, Buzaid A, Ross M. Preoperative chemotherapy with cisplatin, vinblastine and dacarbazine (CVD) in patients with local-regional recurrence of melanoma (AJCC stage-III). Melanoma Research 1995; 5: 449.
13. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981; 193: 337-88.
14. Retsas S. Conference report: First International Conference on the adjuvant therapy of malignant melanoma, London, March 1995. Melanoma Research 1995; 5: 439-40.
15. Retsas S, Quigley M, Pectasides D et al. Clinical and histologic involvement of regional lymph nodes in malignant melanoma: adjuvant vindesine improves survival. Cancer 1994; 73: 2119-30.
16. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Co-operative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
17. Retsas S. Clinical observations on the biology of malignant melanoma: systemic treatment for stage or grade? Melanoma Research 1995; 5: 442-3.